Revenue
2022
2023
2024
2025
Raphael Pharmaceutical Inc. (RAPH)
Price$1.40Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2022
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $631,000 | $776,000 | $569,000 | $1.2M | $776,000 | $461,000 |
| Operating expenses | $1.2M | $1.5M | $1.3M | $3.3M | — | — |
| Operating income | −$1.2M | −$1.5M | −$1.3M | −$3.3M | −$1.6M | −$706,000 |
| EBITDA | −$1.3M | −$1.5M | −$1.3M | −$3.3M | — | — |
| Net income | −$1.3M | −$1.5M | −$1.3M | −$3.4M | −$1.6M | −$718,000 |
| Basic EPSper basic share | $0.07 | $0.08 | $0.08 | $0.23 | $0.15 | $0.07 |
| Diluted EPSper diluted share | $0.07 | $0.08 | $0.08 | $0.23 | $0.15 | $0.07 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Pilo Shlomo | 3.98M |
Louria Hayon Igal | 1.35M |
Dhadha Ajay Kumar | 754.82K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data